Abstract
Objective To explore the feasibility and safety of systemic chemotherapy concurrent whole brain radiotherapy (WBRT) for non-small cell lung cancer (NSCLC) with brain metastases. Methods Eighty cases of NSCLC patients with brain metastases were divided into observation group (40 cases) and the control group (40 cases) according to random number table. Patients were given systemic chemotherapy synchronous WBRT or sequential WBRT. Results The Ⅰ-Ⅳ degree leukocytopenia incidences of the two groups were 12.5%, 25.0%, 25.0%, 0.0 and 30.0%, 25.0%, 12.5%, 15.0%, and there was statistical significance (χ2=12.12, P 0.05). The median progression free survival of the observation group and of the control group were (3.5±2.3) months and (3.6±1.1) months, respec-tively, with no significant difference (t=5.23, P>0.05). But the 1-years survival rate in the observation group was 37.5% (15/40), significantly higher than that in the control group (17.5%, 7/40), which had statistical significance (χ2=9.11, P<0.05). Conclusion The safety of systemic chemotherapy synchronous WBRT for NSCLC patients with brain metastases is higher, with good curative effect and strong application feasibility. Key words: Carcinoma, non-small-cell lung; Neoplasm metastasis; Drug therapy; Whole brain radiotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
